What is open source data? What are the opportunities and obstacles inherent in using open source data? How can companies build products and services around open source data to support clinical and organizational goals for efficiency and effectiveness? These are some of the questions that we will be addressing.
This panel addresses a major challenge and innovation opportunity; the use of massive open source data sets. New businesses are currently being built on public data sets but the manipulation of data for application purposes is just the tip of the information iceberg. Open source data can provide a unique, large, and variably accessible data set upon which new opportunities, both from the data and access to the data, can be pursued. Research advancement, increase in commercialization and new market creation are a few applications for this wealth of accessible information.
1. To address the innovation opportunities inherent in open data, including within its limitations
2. To discuss health challenges that open data help solve
3. To present a business case for the use of open data
Jamie L. Graham
Partner, Kilpatrick Townsend & Stockton LLP
Vice Chair, Georgia BioEd Institute
Jamie Graham focuses her practice on intellectual property issues involving biological and chemical technologies. Ms. Graham conducts domestic and foreign biological and chemical patent prosecution, particularly in the areas of biotechnology, diagnostics, isolation and purification methodology, immunology and pharmaceuticals. She renders patentability, patent validity and freedom-to-operate opinions; performs intellectual property due diligence; and provides advice to clients regarding various aspects of intellectual property, including inventorship determinations, licensing, transactions, pre-litigation and litigation strategies. Ms. Graham has provided intellectual property advice and services to universities, large corporations, small start-up companies and government entities and has been awarded federal and state contracts for patent legal services. Ms. Graham is the Co-Chair of the firm's Health and Life Sciences team.
Ms. Graham has been a registered U.S. Patent Attorney since 1986. Prior to joining the firm, she served as in-house patent counsel for a pharmaceutical company. She has conducted enzyme isolation and characterization research at Sloan-Kettering Institute for Cancer Research and cardiac and allergy drug dispositon/metabolism research at Boehringer Ingelheim Ltd. Ms. Graham also performed graduate research in neuroimmunology and virology (HIV research conducted at the Centers for Disease Control and Prevention). She has been an adjunct professor of Intellectual Property Law at Emory University.
Ms. Graham was listed in The Best Lawyers of America® for Biotechnology and Intellectual Property in 2015 and each of the 14 years immediately preceding. She was also named a 2012 and 2013 "Atlanta Lawyer of the Year" in the area of Biotechnology Law by The Best Lawyers in America®. Ms. Graham was listed in The International Who’s Who of Business Lawyers for Patents in 2013 and in The International Who's Who of Patent Lawyers in 2011. She was recognized in 2009 and 2010 and most recently in 2012, 2013 and 2014 as a Georgia "Super Lawyer" in the area of Intellectual Property by Super Lawyers magazine. Ms. Graham has been recognized as one of Georgia Trend's 2012 "Legal Elite” for Intellectual Property Law. She was
honored by the Georgia Chapter of the Huntington's Disease Society of America at its 2012 Celebration of Hope Gala. Ms. Graham is AV® rated by Martindale-Hubbell.*
David Okou, PhD
Assistant Professor of Pediatrics, Emory School of Medicine
Advisory Board Member, CiDrep
Dr. Okou received his PhD from Clark Atlanta University with training in molecular biology, human genetics and genomic technologies. At Emory, he led the development of a pioneering sample preparation methodology MGS (microarray-based genomic selection (MGS) that selects a user defined target genomic region for high throughput resequencing of eukaryotic genome. His experience and expertise makes use of cutting edge genomic and bioinformatics tools to identify, annotate and interpret low frequency to rare genetic variations that influence disease. He is currently developing research efforts to help fill in the missing heritability gap and understand the molecular mechanism of inflammatory bowel disease (IBD). In particular, He is interested in identifying and functionally testing genetics variants of IBD that will explain early onset cases and phenotypes seen in non-Causasians populations. He believe that an in depth and comprehensive knowledge of the genetics architecture of IBD in non-Causasians populations is vital to the understanding of the genetics of complex diseases and the reasons for diseases differential mechanisms and racial impacts.
Jason Hockenberry, PhD
Associate Professor of Health Policy and Management, Emory University
Independent Consultant in Healthcare Services
Co-Founder, HExPro Analytics, healthcare start-up
Jason Hockenberry, PhD, is a health economist and Assistant Professor in the Department of Health Policy and Management at Emory University. To date he has coauthored 37 articles and book chapters on issues around health policy, and the quality and efficiency of healthcare in the U.S., many of which employ large datasets and complex statistical modelling techniques. Apart from his role at Emory he is also an independent consultant to hospitals and health systems trying to improve their understanding of managing population health and health services use in their market and currently working as part of a team involved in a healthcare forecasting startup. Prior to coming to Emory in 2011 he was on the faculty in the Department of Health Management and Policy at the University of Iowa, where he also served as an investigator in a Veteran’s Affairs Health Services Research and Development Center of Excellence. He received his PhD in Economics from Lehigh University in 2008. Prior to that he served in the U.S. military as an intelligence analyst serving on interim assignments at the National Security Agency and on deployment for a year as part of the UN’s peacekeeping mission in Bosnia.
Chaarles G. Fogelgren, MBA
Global Head, Laboratory Data Management, Global Central Laboratories
Chuck Fogelgren is the Global Head for the Laboratory Data Management organization in Quintiles’ Central Laboratories business. He is responsible for execution and delivery of data management functions as well as developing and executing strategies to improve the services we provide to clinical trials sponsors and patients. Based in Marietta, Georgia, Chuck’s remit is to provide the data management tools and operational leadership to support Quintiles’ growth, pioneer the use of new analytical tools for data management, and partner with customers to deliver industry-leading solutions.
Chuck started his career at the National Academies’ in Washington, DC providing research and project management support to expert committees advising the government on national security issues where science and policy intersect. He spent 7 years in the then fledgling area of biodefense, where he was responsible for leading a new national security program and managing dozens of early drug discovery and development projects with multiple institutes in the Russian Federation.
Chuck later joined Southern Research where he held several leadership roles in the preclinical contract research business including business development, operations, and finally as Director of Business Management. After leaving Southern Research, he spent several years in technology development companies developing new data analysis and security technologies.
Chuck earned his Bachelor of Arts from The George Washington University and his Master of Business Administration from the Kenan-Flagler Business School at The University of North Carolina, Chapel Hill.